₹8.87 Crore Drug Purchases Under Scanner as Aminabad Firms Face Forgery Probe

Lucknow: The Food Safety and Drug Administration (FSDA) has uncovered alleged irregularities in drug purchase and supply records involving several firms operating in Lucknow’s Aminabad area. The probe reportedly concerns transactions worth crores of rupees, including purchases that may have been recorded without corresponding physical supplies.

According to the department’s preliminary findings, questionable invoices, suspected cross-billing and transactions involving a firm that had reportedly ceased operations were identified during the investigation. An FIR has been registered at Aminabad police station against four firm operators, and authorities are examining financial records, invoices and stock details.

The individuals named in the case include Ankur Awasthi of Health Plus, Manish Bajpai of MK Pharma, Govind Shukla of Ram Pharma and Ejaz Ahmad of Patient Care Surgical House in Saharanpur.

Alleged Cross-Billing Raised Questions

Investigators suspect that multiple firms may have used invoices and financial transactions to create records suggesting the purchase and sale of medicines.

The alleged transactions are now being compared with bank statements, purchase bills, stock registers and supplier records. Authorities are attempting to determine whether the medicines mentioned in the documents were actually supplied and moved through the claimed distribution chain.

The investigation will also establish the period during which the alleged transactions took place and whether additional businesses were involved.

Drug Purchases Linked to Closed Firm

A major concern in the investigation relates to Patient Care Surgical House in Saharanpur. According to FSDA officials, drug purchases were reportedly recorded in the firm’s name even though it had allegedly stopped operating nearly two years earlier.

Authorities are examining how transactions could have continued to appear under the firm’s name after its reported closure. Investigators are also checking who controlled the firm’s documentation and whether its details were allegedly used to support paper transactions.

Records associated with Health Plus and Ram Pharma are also being examined to trace the claimed purchase, sale and movement of medicines.

MK Pharma’s ₹8.87 Crore Transactions Examined

The records of MK Pharma have emerged as another key part of the probe. According to the investigation, the firm recorded drug purchases valued at approximately ₹8.87 crore in 2026.

Officials reportedly found a discrepancy involving nearly 39.20 lakh units of Joril M-1. The department is now verifying whether the quantity shown in the records was actually supplied and where the stock was allegedly distributed.

Purchase invoices, stock registers, supplier information and banking records are being examined to establish whether the reported transactions correspond with the physical movement of medicines.

Invoices for Joril M-1, Augmentin and Dexorange Questioned

The investigation has also raised concerns over invoices allegedly relating to Joril M-1, Augmentin and Dexorange syrup.

FSDA officials reportedly contacted the manufacturers to verify the disputed invoices and batch information. According to the department, the manufacturers did not confirm sales corresponding to some of the documents, while certain batch details were reportedly found to be inconsistent or fake.

The findings have prompted authorities to investigate not only possible financial irregularities but also the source and movement of the medicines mentioned in the records.

Police and FSDA Trace Wider Supply Network

Following the FIR, investigators are examining the financial and documentary trail connected with the four firms. Bank transactions, invoices, stock records and other business documents are being scrutinised.

Authorities are also checking whether wholesalers, retailers, suppliers or other companies may have been involved in the alleged transactions.

The investigation is expected to determine the actual value of any questionable transactions, whether medicines were physically supplied against the disputed invoices and whether additional individuals or firms played a role.

At this stage, the individuals named in the FIR are accused and the allegations remain subject to investigation. Further action will depend on documentary evidence, financial records and verification from manufacturers and other parties.